Unless noted otherwise, all reagents, small-molecule inhibitors, and chemotherapies were of the highest grade and purchased from Sigma-Aldrich. Lonidamine was purchased from Tocris Biosciences. Everolimus was purchased from SelleckChem. Doxorubicin and PI103 were purchased from LC Laboratories. All chemotherapeutics and small-molecule inhibitors were dissolved in dimethyl sulfoxide (DMSO) to a stock concentration of 10 mM and kept frozen except for compounds used for animal studies, which were freshly prepared at the indicated concentrations. Recombinant IL-23, IFN-γ, GM-CSF, IL-6, and IL-8 were purchased from BioLegend. The G6PD inhibitor CB-83 was originally reported by Preuss et al. (50) by the ChemBridge ID#6138697, which was purchased from ChemBridge. The G6PD inhibitors, compounds 59, 60, and 61, were obtained from ChemDiv; purity (of >95%) and identity were confirmed by the medicinal chemistry core at Sanford Burnham Prebys by LC-MS and 1H nuclear magnetic resonance (NMR). Analog 59 was 2-(pyridin-3-yl)-3-(p-tolyl)quinazolin-4(3H)-one. Analog 60 was 3-(3-methoxyphenyl)-2-(pyridin-3-yl)quinazolin-4(3H)-one. Analog 61 was 3-(2-methoxyphenyl)-2-(pyridin-3-yl)quinazolin-4(3H)-one.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.